The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Including City and Iambic’s offerings, 26 drug companies have now gone public in 2026, surpassing the annual totals for each of the previous four years, according to BioPharma Dive data.

    Updated 11 hours ago
  • Illustration of laboratory equipment
    Image attribution tooltip

    Cytiva

    Image attribution tooltip
    Sponsored by Cytiva

    Decreasing process variability in fluid management systems

    Discover why flow paths, tubing and connectors may limit your bioprocess performance

  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Belgian startup revives Galapagos CAR-T research

    Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

  • An illustration of a pill over an abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Iambic, an AI drug discovery specialist, banks $150M in an IPO

    Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.”

  • Brain alzheimer's
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit

    In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    OMass Therapeutics’ $310 million Series C round is one of the year’s largest private financings involving the venture firms BioPharma Dive tracks.

    Updated Oct. 15, 2026
  • A photo of Wall Street in New York City in 2022.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Another Paragon spinout goes public through reverse merger

    One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform the reputation for reverse mergers — quickly executing on a complicated deal.

  • Pancreatic cancer cells are stained pink in this micrograph image.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Verastem cancer drug shows early promise in small study

    Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.

  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Roche extends China deal streak with $1B pact for RNAi obesity drug

    An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.

  • Banners marking the 2025 American Society of Clinical Oncology's annual meeting hang from the ceiling of a conference hall.
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive
    Image attribution tooltip

    The top biopharma conferences in 2027

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.

  • CVS
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    CVS to pay $315M to settle opioid prescribing allegations

    Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s claims.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    J&J earnings set ‘negative tone’; Shkreli vs. the FTC

    A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.

  • A 3D illustration of a pair of lungs inside the rib cage.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bristol Myers dips on ‘confounding’ lung drug results

    Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Including its latest deal with Rona Therapeutics, Roche has now inked 10 licensing pacts with China-based drugmakers since the start of 2025. Five have come since late August.

    Updated Oct. 13, 2026
  • A BioNTech logo hangs on the side of an office building.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    BioNTech mRNA cancer immunotherapy misses first objective in key study

    An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.

  • Illustration of a large blue ocean wave cresting against a pale blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pharma’s $500B patent problem will come in waves — not as a cliff

    Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.

  • An illustration of stock market quotes.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    First Tracks climbs on ‘impressive’ celiac study data

    Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential. 

  • Front view of the NASDAQ MarketSite, which occupies the northwest corner at the base of the 4 Times Square building, in Midtown Manhattan, New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    In the hunt for reverse merger targets, Caribou could be prized game

    The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a likely candidate to receive reverse merger interest.

  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Parkinson’s cell therapy developer files to go public

    Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.

  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    This week in charts: What’s driving biotech’s recent pullback?

    The latest installment in BioPharma Dive’s data visualization series features a look at the factors pressuring biotech stocks of late and the frenetic pace of startup buyouts this year. 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

    Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

  • A person in a blue pinstripe suit looks straight ahead.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    HHS launches new plan to strengthen vaccine injury research, reporting

    Spearheaded by vaccine skeptic Robert F. Kennedy Jr., the initiative will involve a new NIH clinic, an updated monitoring system and reimbursements for doctors who report suspected side effects.

    Updated Oct. 9, 2026
    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts

    The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.

  • The building features a modern glass façade with the Nasdaq logo prominently displayed. Surrounding the structure are other commercial buildings and digital billboards, which are characteristic of the vibrant Times Square environment.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    IPO window

    TRex Bio prices $117M IPO to support immune drug work

    Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

  • A corporate building is seen with a sign for the company Viatris
    Image attribution tooltip
    Courtesy of Viatris
    Image attribution tooltip

    Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

    The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.

  • An illustration of the collapse of a stock price
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Argenx falls as Sjögren’s setback offsets celiac drug progress

    A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.